Sickle Cell Has a Cure Now

It's Monday, October twenty-sixth. Sickle cell disease is a genetic blood disorder, and the whole thing comes down to one letter of DNA.

Hemoglobin is the protein inside red blood cells that carries oxygen around your body. Change one letter in the instructions for building it, and hemoglobin clumps together when oxygen drops. The red blood cell folds into a crescent — a sickle — instead of a smooth disc. Those cells are stiff, so they jam in small blood vessels, blood stops moving where it needs to go, and that's a pain crisis. Hours or days of pain that people describe as being stabbed from the inside. Over a lifetime, the blockages damage the spleen, the kidneys, the brain, and the bones.

It's inherited. If both parents carry the trait, each child has a one in four chance. About a hundred thousand Americans have the disease, and it's most common in Black Americans.

For seventy years the treatment was management. Painkillers, transfusions, antibiotics, and hoping the organs held out. There was no cure, only getting through it.

In December 2023, the FDA approved the first medicine that edits a person's DNA to fix the disease. It works. It's called Casgevy, and it costs two point two million dollars per patient.

So the question isn't whether the science worked. It's what happens after the science works.

Victoria Gray was one of them. She grew up in Mississippi, had crises that put her in the hospital for weeks, and by her thirties she was on around-the-clock pain medication. In 2019, she became the first person in the United States to be treated with this approach.

Here's the part I find genuinely strange, because it isn't gene therapy in the way people imagine. Nobody gives you a pill that fixes the gene.

They take stem cells out of your own bone marrow. They edit them outside your body, using CRISPR — a tool that works like a pair of molecular scissors with a GPS attached, cutting at one exact address in the genome.

But they don't cut the sickle mutation. They cut a different gene, one called BCL11A, which acts as the switch that turns off fetal hemoglobin after you're born. Babies make fetal hemoglobin, which doesn't sickle. Then the switch flips and adults make the adult version, which does.

So the edit turns the switch back on. Your body starts making the fetal kind again, and the fetal kind doesn't clump, and the cells don't sickle.

Then comes the part people don't expect. Before they give the edited cells back, they have to clear out your existing bone marrow with chemotherapy. Otherwise the edited cells have nowhere to land. That means a week or two in the hospital, a suppressed immune system, mouth sores, hair loss, and in many cases infertility.

So the cure is a bone marrow transplant where the donor is you and the marrow has been edited.

It works. Patients in the trial stopped having crises. Victoria Gray has described years without the pain that ran her life.

And then the bills, and the beds, and the geography showed up.

Two point two million dollars is the list price. Then you need a hospital that can do the collection, the editing, the chemotherapy, and the weeks of care — and there aren't many, and they have limited beds. Then you need to be well enough to survive the chemo, which rules out people whose organs have already been damaged. The people who need it most are often the people who can no longer take it.

Which is the pattern I keep running into with this stuff. The science is the part that gets the headline and the Nobel. The delivery is the part that decides whether anyone's life actually changes. A cure that exists but sits behind a two-million-dollar price, a specialist center, and a month of your life is a cure for a small number of people.

So the honest state of it is this: for one genetic disease, the thing we said was impossible for seventy years is now a product with a price and a waiting list.

Victoria Gray got her life back. The question the next decade has to answer is how many people get to say that.

Stay informed, stay curious, and we'll see you tomorrow.